Recomendar CONGRESOS.NET Recibir congresos de categoría: Oncología, Informática de la Salud, Congreso, Internacional, MF Congreso
Cerrar

 Recibir gratuitamente información de congresos

Categorías:




Su email:


    > WIN Consortium / Worldwide Innovative...

WIN Consortium / Worldwide Innovative Networking in personalized cancer medicine

6-8 julio 2011- Palais des Congrès de Paris, Porte Maillot. Paris. France


Ficha
Fecha de inicio 06/07/2011 Inicio    Fin  
Webwww.winconsortium.org  
Sede Paris, FranciaLocalidadParisFrancia

OncologíaMédicos: Oncología
Informática de la SaludOtros: Informática de la Salud
CongresoTipo: Congreso
InternacionalÁmbito/Alcance: Internacional
MF CongresoOrganizador: MF Congreso
Paris, FranciaVer en el mapaParis

Descripción
WORLDWIDE INNOVATIVE NETWORKING

6-8 julio 2011
Palais des Congrès de Paris, Porte Maillot

Dear Colleague,

The Worldwide Innovative Networking (WIN) Consortium invites you to attend the third WIN Annual Symposium, dedicated this year to a very challenging topic: Gateways to increasing the efficacy of cancer diagnostics and therapeutics.

The WIN Consortium, initiated by Institut Gustave Roussy (France) and The University of Texas MD Anderson Cancer Center (USA), is a non-profit organization bringing together cancer centers from five continents to address the challenge of increasing the efficacy of global cancer healthcare trough personalized therapy. The WIN Consortium aims to foster and facilitate cooperation between cancer centers, pharmaceutical and technology companies, patient advocacy groups, governmental institutions and other stakeholders in the field of diagnosis and personalized, biomarker-driven treatment of cancer. The goal is to accelerate integration of groundbreaking discoveries into clinical practice in diverse populations, in order to significantly improve clinical outcomes and the quality of life of cancer patients, worldwide.

Examples of questions for discussion and debate during WIN3 include :

* Determining the efficacy of targeted cancer therapies
* Determining the efficacy of genetic and molecular biomarkers for selecting patients likely to respond to targeted therapeutics
* Improved design of clinical trials with targeted therapies. Efficient comparisons. Appropriate endpoints. Combinations of therapies. Is randomization necessary ?
* Building more effective collaborations between academia, industry and patients.
* Innovation in technologies that identify genetic and molecular abnormalities in cancers.
* Improvements in bioinformatics and applications of systems biology.



We aim to create a forum for open discussion, in which your expertise and input from all stakeholders in cancer drug development are crucial. The WIN Consortium was created to accelerate the pace and reduce the cost of translating effective cancer treatments to the bedside. We need every member and thought leader in the field to be committed and engaged to succeed in our mission.

The 22 founding member institutions of the WIN Consortium invite you to join in this forum, and we invite you and your institution to join the Consortium (http://www.winconsortium.org).

John Mendelsohn, M.D.
Chairman of WIN Consortium

Otros congresos relacionados con:


Otros congresos


Categorías (0 congresos en total)

Médicos
Cirugía
Enfermería
Farmacia
Otros
Tipo
ámbito/Alcance
2019    2020    
2021    2022    



Publicitar congreso

No dudes en publicitar congresos gratuitamente en CONGRESOS.NET, envíanos los datos del congreso.

Directorio de proveedores

Donde encontrarás Organizadores de Congresos, OPCs, Hoteles, Agencias de Azafatas... etc.





© 2012 CONGRESOS.NET      Recomendar  -  Aviso legal  -  Mapa web  -  Contacto
Desarrollado por www.brigantia.es